about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Lon­don biotech com­pletes $2.5M mi­cro IPO; AGTC touts ear­ly gene ther­a­py da­ta — but in­vestors keep their dis­tance

4 years ago
News Briefing

As­traZeneca picks up suite of new Covid-19 an­ti­bod­ies, shin­ing spot­light on Ox­ford-tied start­up

4 years ago
Deals
Coronavirus

A CRL lat­er, Gilead clears clin­i­cal hold on next-gen HIV drug — af­ter find­ing a new glass vial for it

4 years ago
FDA+
Manufacturing

Pfiz­er-part­nered Zen­tal­is woos new CEO, cob­bles to­geth­er $200M

4 years ago
People
Financing

Chi­nese Alzheimer's drug­mak­er says lack of fund­ing, Covid out­break forced it to shut­ter in­ter­na­tion­al PhI­II

4 years ago
R&D
China

Seek­ing a come-from-be­hind win, Eli Lil­ly lands big ap­proval for next-gen di­a­betes drug

4 years ago
Pharma
FDA+

Clay Sie­gall re­signs from Seagen amid in­ves­ti­ga­tion in­to do­mes­tic vi­o­lence claims

4 years ago
People

Pfiz­er's $11.6B wa­ger; TIG­IT im­plo­sion; An un­usu­al phar­ma-biotech pact; In­side a16z's vi­sion to re­shape biotech; and ...

4 years ago
Weekly

Quash­ing block­buster hopes, FDA spurns UCB’s IL-17 drug for plaque pso­ri­a­sis

4 years ago
R&D
FDA+

FDA hits Am­i­cus with de­lay on 'break­through' Pompe drug

4 years ago
FDA+

In­ovio's long­time CEO is out as Covid vac­cine lag­gard throws in the tow­el on PhI­II, piv­ots to boost­er

4 years ago
People

Cap­ping a tur­bu­lent saga around Alzheimer's drug, Cor­texyme strikes a deal, brings in new man­age­ment and changes name ...

4 years ago
Deals

Till­man Gern­gross pass­es the Adimab ba­ton af­ter 15 years, mov­ing from CEO to ex­ec­u­tive chair­man role

4 years ago
People

An­oth­er TIG­IT up­date from Ar­cus leaves an­a­lysts read­ing the tea leaves — and the big re­veal is fi­nal­ly near

4 years ago
R&D

Sweep­ing re­org at Ori­on — cen­tered around can­cer and pain — claims 30 staffers

4 years ago
People
Pharma

In wake of do­mes­tic vi­o­lence al­le­ga­tion, long­time Seagen CEO Clay Sie­gall goes on leave

4 years ago
People
R&D

A record num­ber of small biotechs are now trad­ing be­low cash. Is this the bot­tom yet?

4 years ago
Deals

Bio­gen's shake­up from the top; How to build a biotech to­day; David Saba­ti­ni backs out of NYU; and more

4 years ago
Weekly

SEC shines reg­u­la­to­ry spot­light on I-Mab, Sino­vac and oth­ers as more Chi­nese biotechs scram­ble to com­ply with new law

4 years ago
China
FDA+

Jazz dou­bles down on sleep dis­or­ders, putting down $50M cash to pluck Sum­it­o­mo drug for the pipeline

4 years ago
Deals

As­traZeneca adds a ma­jor PhI­II win for Farx­i­ga, set­ting up an­oth­er bat­tle­front with Big Phar­ma ri­vals

4 years ago
R&D

Take­da GI spin­out nabs ap­proval for on­ly drug — and piv­ots to a quick raise

4 years ago
Pharma
FDA+

Days af­ter flag­ging its $773M takeover bid, Zymeworks mi­nor­i­ty share­hold­er adds As­traZeneca on­col­o­gy vet to the crew

4 years ago
People

How do you pack 20 years of ADC learn­ings in­to one com­pa­ny? Tubu­lis has $63M more to an­swer that

4 years ago
Financing
Startups
First page Previous page 31323334353637 Next page Last page
A service from the Financial Times